<DOC>
	<DOC>NCT00543569</DOC>
	<brief_summary>A study to assess the safety and efficacy of Alefacept in de novo kidney transplant patients.</brief_summary>
	<brief_title>A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients</brief_title>
	<detailed_description>This is a 4 arm (all active) study to determine the safety and efficacy of Alefacept in de novo kidney transplant recipients.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subject is anticipated to receive first oral dose of tacrolimus within 48 hours of transplant procedure Subject is a recipient of a de novo kidney transplant Subject is a recipient of a kidney from a nonhuman leukocyte antigen (HLA) identical related living donor, a nonrelated living donor, or a deceased donor Subject has a screening (preoperative)estimated cluster of differentiation (CD) 4+ Tcell count of &lt; 250 cells/ÂµL Subject will receive a kidney with an anticipated cold ischemia time (CIT) of &gt; 30 hours Recipient has a positive T or Bcell cross match by investigational site's standard method of determination Subject will receive a kidney from a 5065 year old deceased donor with one of the following: History of hypertension and a terminal serum creatinine &gt; 1.5 mg/dL Cerebrovascular accident as cause of death and a terminal serum creatinine &gt; 1.5 mg/dL History of hypertension and cerebrovascular accident as cause of death and a terminal serum creatinine &gt; 1.5 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>kidney transplant</keyword>
	<keyword>alefacept</keyword>
</DOC>